Case Report

Erythema elevatum diutinum - Case report of a rare entity

Pooja Desai1, Krina Bharat Patel1,*, Vernon James1, Palak Makwana1, Aanal Patel1
1 Dept. of Dermatology, Venereology, Leprology, GMERS Medical College, Ahmedabad, Gujarat, India

A R T I C L E I N F O

Article history:
Received 18-02-2022
Accepted 05-03-2022
Available online 30-03-2022

Keywords:
Erythema elevatum diutinum
Vasculitis
Dapsone

A B S T R A C T

Erythema elevatum diutinum (EED) is a rare entity of chronic cutaneous vasculitis occurring in association with a variety of conditions including autoimmunity, infectious disease, and hematological abnormalities. The exact pathogenesis of EED is unknown.

A 59-year-old female presented with multiple, itchy, eczematized erythematous papules and plaques over both upper and lower limbs present since 5 months. Histopathological changes were consistent with EED. Patient was started on oral Dapsone 100mg bid along with topical betamethasone dipropionate cream. Within 6 weeks lesions regressed completely leaving post-inflammatory hyperpigmentation. Dapsone was stopped at the end of 3 months. Minor recurrences are managed by topical steroids.

Key Messages: EED is a rare form of vasculitis which is difficult to diagnose clinically, histopathology can be diagnostic. Dapsone is the treatment of choice.

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Erythema elevatum diutinum (EED) is a rare, chronic, cutaneous leukocytoclastic vasculitis characterized by violaceous to red-brown papules and nodules on extensors of extremities.1 The first description of the disease was by Hutchinson and Bury in the 1880s and the condition was later named in 1894 by Radcliffe-Crocker and Williams.2 EED is most commonly seen in adults although occasional childhood cases are reported with no gender and ethnic groups predilection.2 It has been associated with many infections, hematological disorders, connective tissue disorders, and inflammatory disorders. IgA monoclonal gammopathy is the commonest association and myeloma has the strongest association. EED may precede years before hematological abnormality.2

2. Case Report

A 59-year-old female patient presented with itchy reddish skin lesions over arms, legs, buttocks and lower trunk present since 5 months. Lesions started on forearms bilaterally and gradually involved other areas.

Patient was diabetic and hypertensive and was controlled on metformin and amlodipine since 5 years. She had no history of similar lesions in the past and had no significant past history of any cutaneous or systemic disease other than diabetes and hypertension. No complaint of joint pains or fever was present. Patient had consulted dermatologist and was prescribed topical steroids without any significant improvement in lesions.

On clinical examination, multiple, erythematous, papulonodular lesions coalescing into plaques at places were present over extensor aspects of bilateral lower and upper limbs, lower abdomen and gluteal region. Figure 1a,b. No oral or genital mucous membrane lesions were seen. No hair or nail changes were evident. No hepato-splenomegaly or

*Corresponding author.
E-mail address: drkbpatel66@gmail.com (K. B. Patel).
lymphadenopathy were evident.

Considering the clinico-pathological correlation diagnosis of EED was considered. After normal reports of G-6PD level; oral Dapsone 100mg twice daily and topical betamethasone dipropionate cream were prescribed. Patient started improving symptomatically within one week and complete resolutions of lesions were seen after 6 weeks with post-inflammatory hyperpigmentation. Dapsone was tapered to 100mg daily and continued for 3 months by which time PIH also near completely resolved. (Figure 3a,b). Patient is followed up regularly and had no recurrence of lesions for 2 months. Minor recurrences after two months are managed by topical steroids only.

3. Discussion

EED is a rare, chronic dermatosis that can occur at any age with no gender and ethnic groups predilection though it is commonly seen in adults in the fourth to seventh decade. Clinically, lesions present as firm, tender, brownish-red to purple, papules, plaques, or nodules. Extensor aspects of the extremities, usually near joints such as the fingers, hands, elbows, ankles, and knees are the preferred locations. However, occurrences at atypical sites have been reported, including truncal, retroauricular, palmar, and plantar areas. The Lesions of EED are usually asymptomatic, but pruritus, pain and arthralgia may be present.

Early lesions are characterized histologically by leukocytoclastic vasculitis, with neutrophilic perivascular infiltration in the mid-dermis admixed with eosinophils, lymphocytes, plasma cells, and nuclear dust. Late lesions are characterized by mixed inflammatory cell infiltrate, fibrin deposition, cholesterol deposits in histiocytes, and extracellular tissue (extracellular cholesterolosis).

Many reported cases of EED have been described to be associated with a number of systemic diseases including Infections like streptococcal infection, HIV, hepatitis B & c serologies, infections such as inflammatory bowel disease, Wegener’s granulomatosis, relapsing polychondritis, lupus erythematosus and rheumatoid arthritis, hematological disorders such as plasma cell dyscrasias (multiple myeloma), IgA monoclonal gammopathy, lymphomas, and leukemias.

Basic workup and serum electrophoresis in our patient did not reveal any systemic illness. Patient is counseled and is followed up regularly for later development of any systemic disease.

Dapsone is first line management option for EED. Dapsone acts by inhibiting neutrophilic chemotaxis and complement deposition in the vessel wall and suppresses the dysregulation of processes involved in immune complex-induced EED. However, 20% patients do not respond to dapsone or do not tolerate the drug and recurrence after stopping the drug is seen in around 32% cases. The present case responded to dapsone with complete resolution and only minor recurrences after stopping dapsone till date in
follow up over 2 years.

4. Conflict of interest

The authors declare they have no conflict of interest.

5. Source of funding

No financial support was received for the work within this manuscript.

References


Author biography

Pooja Desai, 3rd Year Resident

Krina Bharat Patel, Professor and Head

Vernon James, 2nd Year Resident

Palak Makwana, Senior Resident

Aanal Patel, 2nd Year Resident